[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","qjtv6lb7s73tn4urnunjsmfd9","revision",2,"title","Telix Pharmaceuticals Limited 发布2026年第三季度财务表现","originalTitle","6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)","summary","Telix Pharmaceuticals Limited 发布2026年第三季度财务表现报告。报告包含公司财务数据及运营情况。该报告已提交至澳大利亚证券交易所。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-20T23:40:59.000Z","discoveredAt","2026-10-21T10:04:05.046Z","timelineAt","category","ai-products","tags",[81,82,83],"stockSymbols",[80],"score",25,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":14,"_68":69,"_70":71},"hasTranslation","bodyLanguage","original","factId","fVm3QYTixz98",{"_72":73,"_15":74},"reportCount","additionalSourceCount",1,"developmentCount",0,"publicId","c7c5f6e7-e823-4935-b8de-adbc9aefddce","Telix 公布 2026 年第三季度财务表现",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 21, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the

Australian Securities Exchange titled “Telix Reports Third Quarter 2026 Financial Performance” a copy of which is

attached to this Form 6-K as Exhibit 99.1.


99.1	Press release – October 21, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned, thereunto duly authorized.



		Telix Pharmaceuticals Limited

Date:	October 21, 2026	By:	/s/ Christian Krautkramer
			Name: Christian Krautkramer
			Title: Group General Counsel

","zhKind","complete","TLX","公司与财报","财报","退市","aihot","/items/qjtv6lb7s73tn4urnunjsmfd9","https://www.sec.gov/Archives/edgar/data/2007191/000162828026066581/0001628280-26-066581-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792800000&sig=a1281a539589308a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792800000&sig=57a86ea6a382db0f 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792800000&sig=f9807010575fb678 96w","changelogVersion","2026-10-01T08:00"]